NASDAQ$TMDX
TransMedics Group Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
TransMedics reported Q1 2026 total revenue of $173.9M (+21% YoY), net income of $7.3M, and diluted EPS of $0.20.
For the three months ended March 31, 2026, TransMedics generated total revenue of $173.9 million, up from $143.5 million, with net product revenue of $108.0 million and service revenue of $66.0 million. Net income was $7.3 million ($0.20 diluted EPS) versus $25.7 million in Q1 2025 when margins were unusually high. OCS transplant adoption in the U.S. drove volume growth across liver and multi-organ platforms.
- Total revenue $173.9M (+21% YoY).
- Net income $7.3M; diluted EPS $0.20 vs. $0.70 prior year.
- U.S. OCS revenue $167.0M (+17%) on higher disposable utilization.
- Service and NOP logistics revenue growing with center penetration.
- Gross profit pressured by mix and service cost ramp.
Headline financials
Revenue & EPS history
TransMedics · Revenue · Quarterly
$174M
Forward guidance
MD&A highlights center additions, NOP utilization, and international expansion without formal annual EPS targets.
Tailwinds
- Continued U.S. transplant volume growth.
- Product and service revenue both expanding.
Headwinds
- Year-over-year net income down on cost investments.
- Capital intensity of national OCS network.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+4.1%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.6%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+42.6%
Q3 2023
Best reaction
-29.3%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.1% | -30.0% | -26.4% | |
| Q4 2025 | -4.6% | -3.6% | -35.1% | |
| Q3 2025 | +0.9% | -9.0% | +8.9% | |
| Q1 2025 | +19.6% | +31.3% | +49.2% | |
| Q4 2024 | +5.8% | -6.5% | -4.9% | |
| Q3 2024 | -29.3% | -34.2% | -30.4% | |
| Q2 2024 | +9.4% | +7.2% | +21.4% | |
| Q1 2024 | +20.9% | +31.6% | +40.3% | |
| Q4 2023 | +6.7% | -0.5% | -10.8% | |
| Q3 2023 | +42.6% | +34.6% | +73.5% | |
| Q2 2023 | -8.9% | -24.7% | -21.5% | |
| Q1 2023 | -6.7% | -6.4% | -8.1% | |
| Q4 2022 | +20.2% | +20.4% | +15.4% | |
| Q3 2022 | +20.7% | +17.6% | +38.7% | |
| Q2 2022 | -7.7% | +20.8% | +28.9% | |
| Q1 2022 | +39.5% | +25.4% | +29.5% | |
| Q4 2021 | +23.2% | +39.5% | +82.5% | |
| Q3 2021 | -12.0% | -16.3% | -29.0% | |
| Q2 2021 | +9.6% | +7.6% | +17.2% | |
| Q1 2021 | -12.6% | -15.1% | -11.3% | |
| Q4 2020 | +3.4% | -12.3% | +10.6% | |
| Q3 2020 | +4.8% | +10.6% | +20.8% | |
| Q2 2020 | +0.1% | -3.2% | -11.9% | |
| Q1 2020 | -7.6% | -0.6% | -11.7% | |
| Q4 2019 | -1.1% | -1.2% | -25.7% | |
| Q3 2019 | -14.2% | -13.0% | -1.7% | |
| Q2 2019 | -4.2% | -4.6% | +8.6% | |
| Q1 2019 | -2.3% | -2.1% | -4.1% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro